# Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

> **NCT00569335** · PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 52 (actual)

## Conditions studied

- Colorectal, Cancer

## Interventions

- **DRUG:** S-1, Irinotecan, Bevacizumab

## Key facts

- **NCT ID:** NCT00569335
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2012-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569335, "Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00569335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*